Preeti Narayan, MD @pre_ryan

Breast Oncologist at FDA, @FDAOncology Opinions are my own. Canadian/American hybrid 🇨🇦🇺🇸 fda.gov/about-fda/fda-… Washington, DC Joined February 2015

Tweets

228
Followers

383
Following

104
Likes

3K

FDA Oncology @FDAOncology

9 months ago

#FDA approves a treatment for unresectable or metastatic HER2-positive breast cancer. ow.ly/gApl50XJP1c

0 11 15 5K 5

View Details

Dr. Kelly Shanahan @stage4kelly

2 years ago

Unfortunately, other obligations kept me and @JaniceTNBCmets from attending our favorite @abreastcancer session with the FDA, but nothing could keep us from at least saying hi to some of our favorite @FDAOncology people! @tmprowell #SABCS24

0 5 23 4K 0

View Details

FDA Oncology @FDAOncology

2 years ago

FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer. fda.gov/drugs/resource… #OCENewsBurst

1 15 15 10K 2

View Details

FDA Oncology @FDAOncology

2 years ago

What are pragmatic clinical trials? Clinical trials that streamline data collection and design by collecting only necessary information to answer the research question. A thread 🧵 1/5 #ProjectPragmatica #OCEProject5in5 #PragmaticTrials

2 45 78 16K 36

View Details

Preeti Narayan, MD @pre_ryan

2 years ago

@NBCCStopBC Thank you for having us, was great to be part of the panel

0 0 1 11 0

View Details

Preeti Narayan, MD @pre_ryan

2 years ago

Mentioned this OCE initiative at @NBCCStopBC Advocate summit today at the outcomes that matter panel discussion, please post any ideas for pragmatic designs! @FDAOncology @drjennifergao @DrKNorsworthy @StevenClarkCunn @DrDonnaRivera

FDA Oncology @FDAOncology

2 years ago

What is FDA Oncology's Project 5 in 5? ⏩ OCE Director Dr. Richard Pazdur explains how 𝘆𝗼𝘂 can take part in crowdsourcing to ultimately select 5 clinically relevant questions to be answered in pragmatic clinical trials. shareyourvoice.ideascalegov.com/c/ #OCEProject5in5

1 18 19 11K 2

1 3 7 767 0

View Details

Julia Maués @itsnot_pink

2 years ago

“Dose is the foundation of drug development. Having the wrong dose is like building a house on quicksand.” @realrickpazdur, quoted by @pre_ryan at @NBCCStopBC’s #NBCCSummit.

1 9 27 1K 1

View Details

Preeti Narayan, MD @pre_ryan

2 years ago

@DrMMurphy @UFMedicine @UF Congrats!!! So well deserved!

0 0 2 32 0

View Details

National Breast Cancer Coalition @NBCCStopBC

2 years ago

Today’s #NBCCSummit panel includes @theNCI’s Larissa Korde, @pre_ryan, NBCC team leader Nicole Seagriff, and @QueensGlobalOnc’s Brooke Wilson about why oncology research should be designed to answer questions about outcomes and questions that matter for patients.

1 3 6 575 0

View Details

FDA Oncology @FDAOncology

2 years ago

🎇 Today, Sunday, May 5 - #CincodeMayo - We officially launch Project 5 in 5: Crowdsourcing 5 clinically relevant questions for 5 pragmatic clinical trials! 💡 What's your clinical trial idea? Sign up and submit ideas here ➡️ shareyourvoice.ideascalegov.com/c/ #OCEProject5in5

1 7 13 4K 0

View Details

Harpreet Singh, MD @harpreet_md

2 years ago

✨Perfect day spending time with colleagues and friends ✨@FDAOncology

0 1 18 959 0

View Details

FDA Oncology @FDAOncology

2 years ago

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. fda.gov/drugs/resource… #OCENewsBurst

1 55 93 47K 7

View Details

Preeti Narayan, MD @pre_ryan

3 years ago

@DrSGraff @FDAOncology @SABCSSanAntonio Really appreciated the opportunity to have this session at #SABCS23

0 0 4 82 0

View Details

Stephanie Graff, MD, FACP, FASCO @DrSGraff

3 years ago

I want to say I appreciate @FDAOncology coming out from behind the curtain and discussing with patients and clinicians their thoughts & rationale around recent approvals. Great session, @SABCSSanAntonio 👏🏻

4 11 58 10K 0

View Details

FDA Oncology @FDAOncology

3 years ago

The latest episode of #OCEProjectLivinLabel - fam-Trastuzumab Deruxtecan-nxki: The Backstory – is now available! Watch the episode and read the labeling to receive free CME credit offered by @AACR. Click here 🔽 aacr.org/professionals/… @pre_ryan #OCEProjectSocrates

0 2 7 1K 1

View Details

Oncology Brothers @OncBrothers

3 years ago

#SABCS23 Day 1 Highlights #CommunityOnc: @FDAOncology Review on recent approvals 1. #CAPItello291 2. #EMERALD 3. #TDxD 4. Tumor Agnostic landscape 5. Post CDK4/6i HR+ @SABCSSanAntonio @VivekSubbiah @VKaklamani @JaniceTNBCmets #bcsm @DrSGraff @oreganruth 1/6

2 38 104 16K 31

View Details

Elisa Agostinetto @ElisaAgostinett

3 years ago

Great start at #SABCS23 with the session on New approval in metastatic #breastcancer 🔸Elacestrant 🔸T-DXd 🔸Capivasertib Happening now at Hemisfair Ballroom 1-2 @SABCSSanAntonio @OncoAlert

0 6 18 2K 0

View Details

FDA Oncology @FDAOncology

3 years ago

FDA approved capivasertib with fulvestrant for HR+ HER2-neg locally advanced/metastatic breast cancer with PIK3CA/AKT1/PTEN alterations following progression on endocrine-based regimen or recurrence on completing adjuvant therapy fda.gov/drugs/resource… Click to #OCENewsBurst ⬆️

0 10 14 10K 1

View Details

FDA Oncology @FDAOncology

3 years ago

Today FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent dMMR or MSI-H endometrial cancer. fda.gov/drugs/drug-app…

1 15 28 8K 1

View Details

Preeti Narayan, MD @pre_ryan

3 years ago

Important article for the oncology community on drug shortages and FDA's role, root causes for these shortages, and strategies to address -link is open access @OncoAlert

FDA Oncology @FDAOncology

3 years ago

Read an interview with OCE Director Richard Pazdur about causes of oncology drug shortages and what the FDA can and can't do to fix it, via @TheCancerLetter open access article.